
AMENDMENTS TO THE CLAIMS

The following Listing of Claims replaces all prior versions, and listings, of claims.

LISTING OF CLAIMS

1. (Currently Amended) A liquid, aqueous composition comprising
 - (i) A a factor VII polypeptide;
 - (ii) A an agent suitable for keeping pH in the range of from about 5.5 to about 7.0;
 - (iii) A an agent selected from the list of: a calcium salt in a concentration of at least 200 mM, such that the composition is hypertonic, a magnesium salt, or a mixture thereof, wherein the concentration of (iii) is at least 20 mM and wherein said factor VII polypeptide composition retains at least 50% of its initial biological activity upon storage of said aqueous composition for 6 months at 2-8°C.
2. (Previously Amended) A composition according to claim 1, further comprising (iv) an ionic strength modifying agent.
3. (Original) A composition according to claim 2, wherein the ionic strength modifying agent (iv) is selected from the list of: a neutral salt, e.g., sodium chloride; an amino acid; or a small peptide, or a mixture of at least two of said modifying agents.
4. (Original) A composition according to claim 3, wherein the ionic strength modifying agent (iv) is sodium chloride.
5. (Cancelled).
6. (Original) A composition according to claim 2, wherein the agent (iv) is present in a concentration of at least about 5 mM.

-
7. (Original) A composition according to claim 1, wherein the calcium salt is selected from the group consisting of: calcium chloride, calcium acetate, calcium gluconate, and calcium laevulate.
 8. (Cancelled).
 9. (Cancelled).
 10. (Original) A composition according to claim 1, further comprising (v) a tonicity modifying agent.
 11. (Previously Amended) A composition according to claim 10, wherein the tonicity modifying agent (v) is selected from the group consisting of: a neutral salt; a monosaccharide; a disaccharide; polysaccharide; a sugar alcohol; an amino acid; a peptide, and a mixture of at least two of said modifying agents.
 12. (Original) A composition according to claim 10, wherein the tonicity modifying agent (v) is present in a concentration of from 1 mM to 500 mM
 13. (Currently Amended) A composition according to claim 12, wherein the concentration of the tonicity modifying agent is between 10 – 250 mM.
 14. (Original) A composition according to claim 1, further comprising (vi) a non-ionic surfactant.
 15. (Original) A composition according to claim 14, wherein the non-ionic surfactant is a polysorbate or a poloxamer or a polyoxyethylene alkyl ether.
 16. (Original) A composition according to claim 1, further comprising (vii) an antioxidant

-
17. (Currently Amended) A composition according to claim 16, wherein the antioxidant (vii) is selected from the group consisting of: L- or D-methionine, -ascorbic acid, cysteine, homocysteine, glutathione, cystine, and cystathionine.
18. (Original) A composition according to claim 17, wherein the antioxidant is L-methionine.
19. (Original) A composition according to claim 16, wherein the antioxidant is present in a concentration of from about 0.1 to about 5.0 mg/ml.
20. (Cancelled).
21. (Previously Amended) A composition according to claim 1, wherein the agent suitable for keeping pH in the range of from about 5.5 to about 7.0 is selected from the group consisting of acids and salts of: citrate, acetate, histidine, malate, phosphate, tartaric acid, succinic acid, MES, HEPES, Imidazol, TRIS, lactate, glycylglycin, PIPES, gycin, and a mixture of at least two of said agents.
22. (Original) A composition according to claim 21, wherein the concentration of the agent is from about 1 mM to about 50 mM.
23. (Previously Amended) A composition according to claim 22, wherein the concentration of the agent is about 10 mM.
24. (Original) A composition according to claim 1, further comprising (viii) a preservative selected from the group consisting of phenol, benzyl alcohol, orto-cresol, meta-cresol, para-cresol, methyl paraben, propyl paraben, benzalconium chloride, and benzaethonium chloride.
25. (Original) A composition according to claim 1, wherein said factor VII polypeptide is stable for at least 6 months at 2-8°C.
26. (Original) A composition according to claim 1, wherein the factor VII polypeptide is recombinantly made human factor VIIa.

27. (Cancelled).

28. (Cancelled).

29. (Original) A composition according to claim 1, wherein the factor VII polypeptide is present in a concentration of from about 0.1 mg/ml to about 10 mg/ml.

30. (Currently Amended) A method for preparing a liquid, aqueous composition of a factor VII polypeptide, comprising the step of providing the factor VII polypeptide in a solution comprising (ii) an agent suitable for keeping pH in the range of from about 5.5 to about 7.0; (iii) ~~an agent selected from the group consisting of:~~ a calcium salt in a concentration of at least 200 mM, such that the composition is hypertonic, a magnesium salt, or a mixture thereof; wherein ~~the concentration of~~ (iii) is at least 20 mM, and wherein said factor VII polypeptide composition retains at least 50% of its initial biological activity upon storage of said aqueous composition for 6 months at 2-8°C.

31. (Currently Amended) A method for treating a factor VII-responsive syndrome, the method comprising administering to a subject in need thereof an effective amount of an aqueous liquid composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 5.5 to about 7.0; (iii) ~~an agent selected from the group consisting of:~~ a calcium salt in a concentration of at least 200 mM, such that the composition is hypertonic, a magnesium salt, or a mixture thereof; wherein ~~the concentration of~~ (iii) is at least 20 mM, and wherein said factor VII polypeptide composition retains at least 50% of its initial biological activity upon storage of said aqueous composition for 6 months at 2-8°C.

32. – 37. (Cancelled).